Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Gyre Therapeutics (GYRE) Loans and Notes Receivables (2022 - 2026)

Gyre Therapeutics has reported Loans and Notes Receivables over the past 4 years, most recently at $5.6 million for Q4 2025.

  • Quarterly Loans and Notes Receivables rose 28.93% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, up 28.93% year-over-year, with the annual reading at $5.6 million for FY2025, 28.93% up from the prior year.
  • Loans and Notes Receivables was $5.6 million for Q4 2025 at Gyre Therapeutics, up from $693000.0 in the prior quarter.
  • Over five years, Loans and Notes Receivables peaked at $5.6 million in Q4 2025 and troughed at $91000.0 in Q3 2024.
  • The 4-year median for Loans and Notes Receivables is $596000.0 (2025), against an average of $1.6 million.
  • Year-over-year, Loans and Notes Receivables crashed 74.44% in 2023 and then skyrocketed 1024.16% in 2024.
  • A 4-year view of Loans and Notes Receivables shows it stood at $1.5 million in 2022, then crashed by 74.44% to $389000.0 in 2023, then skyrocketed by 1024.16% to $4.4 million in 2024, then rose by 28.93% to $5.6 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Loans and Notes Receivables are $5.6 million (Q4 2025), $693000.0 (Q3 2025), and $499000.0 (Q2 2025).